RecruitingPHASE1, PHASE2NCT04998396
A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)
Studying Canavan disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Aspa Therapeutics
- Intervention
- AAV9 BBP-812(biological)
- Enrollment
- 26 enrolled
- Eligibility
- All sexes
- Timeline
- 2021 – 2030
Study locations (4)
- UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Massachusetts General Hospital (MGH); Center for Rare Neurological Diseases (CRND), Boston, Massachusetts, United States
- Weill Cornell Medicine; Division of Pediatric Neurology, New York, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04998396 on ClinicalTrials.govOther trials for Canavan disease
Additional recruiting or active studies for the same condition.